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Gene expression profiling of  
pre-eclamptic placentae by RNA 
sequencing
Tea Kaartokallio1, Alejandra Cervera2, Anjuska Kyllönen1, Krista Laivuori1,3,4, Juha Kere3,4,5 & 
Hannele Laivuori1,6,7,  The FINNPEC Core Investigator Group†
Pre-eclampsia is a common and complex pregnancy disorder that often involves impaired placental 
development. In order to identify altered gene expression in pre-eclamptic placenta, we sequenced 
placental transcriptomes of nine pre-eclamptic and nine healthy pregnant women in pools of three. 
The differential gene expression was tested both by including all the pools in the analysis and by 
excluding some of the pools based on phenotypic characteristics. From these analyses, we identified 
altogether 53 differently expressed genes, a subset of which was validated by qPCR in 20 cases and 
19 controls. Furthermore, we conducted pathway and functional analyses which revealed disturbed 
vascular function and immunological balance in pre-eclamptic placenta. Some of the genes identified 
in our study have been reported by numerous microarray studies (BHLHE40, FSTL3, HK2, HTRA4, LEP, 
PVRL4, SASH1, SIGLEC6), but many have been implicated in only few studies or have not previously 
been linked to pre-eclampsia (ARMS2, BTNL9, CCSAP, DIO2, FER1L4, HPSE, LOC100129345, LYN, 
MYO7B, NCMAP, NDRG1, NRIP1, PLIN2, SBSPON, SERPINB9, SH3BP5, TET3, TPBG, ZNF175). Several 
of the molecules produced by these genes may have a role in the pathogenesis of pre-eclampsia, and 
some could qualify as biomarkers for prediction or detection of this pregnancy complication.
Pre-eclampsia, a vascular pregnancy disorder characterised by new-onset hypertension and proteinuria, 
affects approximately 3–5% of all pregnancies1,2. The disease causes over 63 000 maternal deaths yearly, 
and is one of the major causes for premature birth3. Pre-eclampsia is considered to have a multifactorial, 
polygenic etiology that, despite intensive research, remains elusive. The syndrome likely includes several 
subtypes4,5. According to a prevalent theory, early-onset pre-eclampsia accompanied with fetal growth 
restriction involves poor placental development, whereas in the late-onset form pre-existing maternal 
cardiometabolic risk factors might play a more significant role6.
For certain subtypes of pre-eclampsia, there is strong evidence for the involvement of disturbed 
placental development7,8. During normal placentation, fetal extravillous trophoblast cells invade into 
the uterine wall, and together with other modifying cells transform maternal spiral arteries wider and 
less resistant, and thus better adapted for supplying adequate blood flow for the fetus. In pre-eclampsia 
the extravillous trophoblast invasion is shallower and the modification of arteries insufficient7,9, which 
leaves the arteries narrower and more contractile, and subsequently increases resistance and fluctuations 
in placental blood flow10–12. Due to still unknown mechanisms that may involve cell necrosis caused 
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by oxidative and mechanical shear stress, pre-eclamptic placenta releases excess amount of placental 
material into maternal circulation13,14. Placental factors, such as antiangiogenic soluble fms-like tyros-
ine kinase-1 (sFlt-1)15,16, are believed to trigger systemic inflammation and endothelial dysfunction that 
manifest as the maternal symptoms of hypertension and proteinuria17,18.
As placenta is centrally involved in the pathophysiology of pre-eclampsia, gene expression in 
pre-eclamptic placentae has been studied extensively with microarrays19–21. According to a recent system-
atic review, the genes most frequently differently expressed, LEP and FLT1, had been found in only third 
of the studies19, indicating inconsistency between the expression studies reviewed. This might be partly 
explained by the phenotypic and etiologic heterogeneity of pre-eclampsia, as well as by the differences in 
study design for factors that affect placental gene expression such as gestational weeks, sex of the child or 
method of delivery. Moreover, technical reasons including differences in placental sampling site, sample 
handling, microarray platforms and statistical methods add further heterogeneity between the studies.
To the authors’ knowledge, this is the first study to apply RNA sequencing (RNA-seq) in studying 
gene expression in pre-eclamptic placenta. Studies comparing performance of microarrays to that of 
RNA-seq have revealed several advantages of the latter22–25. Among these is the wider dynamic range 
of RNA-seq, due to which it is more sensitive in detecting genes with low expression level. Moreover, 
RNA-seq is not probe-based and therefore has a better genomic coverage. Thus, RNA-seq outperforms 
microarrays in sensitivity and is able to survey larger amount of genes, giving this method potential to 
reveal differential expression for genes not previously linked with pre-eclampsia. Identifying genes with 
altered expression in pre-eclamptic placenta would help to discover molecular mechanisms involved in 
the development of this common pregnancy disorder, as well as molecules qualifying for the prediction 
and detection of this disease.
Results
Clinical characteristics. Clinical characteristics of the study subjects are presented in Table 1. In addi-
tion to diagnostic criteria of pre-eclampsia, the cases and controls in the RNA-seq differ statistically sig-
nificantly for parity, gestational age at birth, relative birth weight and delay from detachment of placenta 
to sampling. In the sample set used for the quantitative PCR (qPCR) validation, the case and control 
groups differ for parity, relative birth weight and delay from detachment of placenta to sampling (Table 1).
Quality control of the RNA-seq data. On average, 1.85% of the original RNA-seq reads were fil-
tered out in the quality filtering step, the percentage of filtered reads per pool being between 1.6 and 
2.0%. After trimming and filtering, the quality of each forward and reverse pool was assessed. Read 
lengths for the forward data were between 25 and 101 bases for every pool whereas for the reverse data 
read length ranged between 25–90 and 25–101 bases depending on the pool. The average GC content per 
pool was 48–50%. The number of reads per pool after trimming and filtering ranged from 29 358 515 
to 39 060 015 reads, the average of all pools being 32 670 939. The pools contained 64.6–73.6% dupli-
cate reads, the average of all pools being 68.8%. The quality metrics for the RNA-seq data are shown in 
Supplementary Table S1.
After quality trimming and filtering, the reads were aligned to the reference genome. Quality metrics 
for the alignment are shown in Supplementary Table S2. Approximately 94% of the reads mapped with 
mate. For only 1% of these reads, the paired reads mapped to different chromosomes, indicating that 
majority of the reads aligned correctly. On average, 91% of the alignments were unique, aligning to only 
one position in the reference genome. Of the reads mapping to the annotated genes, on average 14.7% 
mapped to the top 10 most highly expressed genes and 19.8% to the top 20 most highly expressed genes. 
These numbers may partly explain the high numbers of duplicate reads as the abundant transcripts are 
more likely to be sequenced multiple times. Hence, many of the duplicate reads probably stem from high 
gene expression rather than from PCR duplication, therefore representing a true biological phenomenon.
Differential gene expression in the RNA-seq. The differential gene expression was tested utilising 
three strategies. First, all the pre-eclampsia pools were compared against all the control pools. Second, 
the pre-eclampsia pools 2 and 3 were compared against the control pools. The pre-eclampsia pool 1 was 
excluded as it contained a Trisomy 21 placenta (information on Trisomy 21 diagnoses were not available 
at the time of the sample selection), and also because it may represent less severe pre-eclampsia pheno-
type as all the placental samples in this pool originate from term deliveries without fetal growth restric-
tion. Third, the pre-eclampsia pools 1 and 2 were compared against the control pools. The pre-eclampsia 
pool 3 was excluded because it differed most from the control pools for gestational age. From these three 
subanalyses, we obtained altogether 53 genes that were statistically significantly differently expressed 
between the case and control groups, when the Y chromosomal genes were excluded, as the fetal sex 
distribution between the groups was not equal. The overlap in the results from the different subanalyses 
is illustrated in Fig.  1. The differently expressed genes along with their summarised function, protein 
localisation, and expression difference (log2 fold change) are listed in Table 2, and the expression profiles 
of the genes per subanalysis are shown in Fig. 2. The detailed result files containing differently expressed 
genes in each subanalysis are found in Supplementary Table S3.
Altogether 577 distinct genes had a log2 fold change ≥ 1 or ≤ −1 (two-fold difference) in at least one of 
the subanalyses, when the Y chromosomal genes were again excluded. Among these genes are FLT1, INHBA, 
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CRH, PAPPA2 and LHB, genes often differently expressed in pre-eclampsia. The overlap in the genes with a 
log2 fold change ≥ 1 or ≤ −1 between the subanalyses is illustrated in the Supplementary Fig. S1.
Pathway and functional analyses. Gene set enrichment analysis. Gene set enrichment analysis 
(GSEA) was conducted for each subanalysis independently. The analysis was carried out twice using two 
separate gene sets (hallmark gene sets and canonical pathways gene sets). With the hallmark gene sets 
16, 10 and 10 pathways, and with the canonical pathways gene sets 72, 60 and 84 pathways were statisti-
cally significant in the analyses with all the pools included, with pre-eclampsia pool 1 excluded and with 
pre-eclampsia pool 3 excluded, respectively. Immunological as well as autoimmune and inflammatory 
disease pathways were enriched among significant pathways. Also signal transduction pathways that con-
trol growth and differentiation were abundant. Other significant pathways were related to developmental 
processes such as extracellular matrix and tissue remodelling, angiogenesis and epithelial-mesenchymal 
transition as well as to DNA damage response and reactive oxygen species. The significant pathways from 
the analyses utilising hallmark gene sets are shown in Table 3 and the pathways from the analyses with 
canonical pathways gene sets in Supplementary Table S4.
Ingenuity canonical pathway analysis. The genes with at least two-fold increase or decrease in 
expression in the pre-eclamptic placentae compared to the control placentae (log2 fold change ≥ 1 or 
≤ −1) were included in the Ingenuity Pathway analysis (IPA) conducted separately for each subanalysis. 
Altogether 44, 60 and 41 canonical pathways were statistically significant in the analysis with all the 
pools included, with pre-eclampsia pool 1 excluded and with pre-eclampsia pool 3 excluded, respec-
tively. Multiple immunological functions from both innate and adaptive immune systems were altered 
in pre-eclamptic placenta. Many of the significant pathways were related to autoimmune disease, such 
Maternal or perinatal characteristic
RNA-seq qPCR validation
Controls (n = 9) Cases (n = 9) p Controls (n = 19) Cases (n = 20) p
Age (years) 32.3 ± 3.6 34.0 ± 5.5 0.46 30.8 ± 5.2 33.2 ± 5.9 0.20
BMI (kg/m2) 21.5 (20.2/24.3) 22.6 (21.7/25.1) 0.26 23.0 (20.3/27.7) 23.3 (21.4/25.6) 0.75
Before pregnancy smokers 3 (33.3%) 1a (12.5%) 0.58 5a (27.8%) 2 (10.0%) 0.22
During pregnancy smokers 0 0a − 1a (5.6%) 0 0.47
Parity
 -Primipara 1 (11.1%) 6 (66.7%) 7 (36.8%) 15 (75.0%)
 -Multipara 8 (88.9%) 3 (33.3%) 0.050 12 (63.2%) 5 (25.0%) 0.016
Systolic blood pressure (mmHg) 121.0 (119.5/126.0) 168.0 (154.5/179.5) < 0.001 121.0 (117.0/126.0) 168.5 (159.3/174.8) < 0.001
Diastolic blood pressure (mmHg) 80.0 (76.5/83.5) 111.0 (101.0/117.5) < 0.001 80.0 (77.0/83.0) 110.0 (105.0/118.3) < 0.001
Proteinuria (g/24 h) − 3.43 (2.19/5.65) − − 4.19 (1.40/8.27) −
Gestational diabetes 0 0 − 2 (10.5%) 2 (10.0%) 1.00
Gestational age at birth (weeks) 39.1 (39.1/39.4) 36.0 (33.4/38.3) 0.006 39.0 (35.1/39.3) 36.4 (33.0/39.2) 0.18
Relative birth weight 0.62 (− 0.63/1.83) − 1.97 (− 2.38/− 0.58) 0.019 − 0.33 (− 1.1/0.62) − 1.43 (− 1.99/− 0.56) 0.003
Method of delivery
 -Vaginal 0 0 7 (36.8%) 7 (35.0%)
 -C-section 9 (100%) 9 (100%) − 12 (63.2%) 13 (65.0%) 0.91
Contractions 0 0 − 7 (36.8%) 8 (40.0%) 0.84
Sex of child
 -Boy 5 (55.6%) 4 (44.4%) 8 (42.1%) 11 (55.0%)
 -Girl 4 (44.4%) 5 (55.6%) 1.0 11 (57.9%) 9 (45.9%) 0.42
Delay from detachment of placenta to 
sampling (min) 23.0 (18.5/26.0) 43.0 (25.5/57.5) 0.008 23.0 (18.0/29.0) 31.5 (24.3/44.5) 0.008
Table 1.  Clinical characteristics of the study population. Continuous variables: data are presented as 
mean ± standard deviation for the normally distributed data (maternal age) and as median (25th/75th percentile) 
for the data that is non-normally distributed in at least one of the sample sets (BMI, blood pressure, gestational 
age at birth, relative birth weight and delay from detachment of placenta to 9-site sampling). Variables were 
compared using an independent samples t-test for parametric data and an independent samples Mann-Whitney 
U test for non-parametric data. Discontinuous variables: data are presented as frequencies (%). Variables were 
compared using chi square test or Fisher’s exact test for the variables with less than five observations in at least 
one cell. BMI: body mass index; C-section: Caesarean section. ainformation missing for one study subject.
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as rheumatoid arthritis and systemic lupus erythematosus. Also pathways related to migration, tissue 
development and angiogenesis as well as to stress response and signalling were enriched. The complete 
list of the pathway analysis results can be found in Supplementary Table S5.
Ingenuity pathway functional analysis. The disease and functional annotations that were most 
significant in all the subanalysis are related to vast amount of immunological functions, tissue devel-
opment, cell movement and cell communication and signalling. Other significant annotation categories 
include autoimmune and inflammatory diseases, cell death and cell proliferation, oxidative stress, car-
diovascular disease and cardiovascular system development and function. The categories that included 
most disease and function annotations in the functional analysis and selected additional categories are 
presented in Supplementary Table S6 and the complete lists of the significant annotations can be found 
in Supplementary Table S7.
qPCR validation. Of the total number of 53 genes that were differently expressed in the RNA-seq, 
12 were originally selected for further qPCR validation. Due to the sequence similarity between DEFA1 
and DEFA1B, the Taqman assays are not able to separate their expression from one another and the 
same assay detects expression of both making the number of assays utilised in the qPCR validation 11. 
In the qPCR analysis we focused on distinguishing the disease-related gene expression differences from 
the differences caused by variability in gestational age. The effect of pre-eclampsia and gestational age on 
gene expression was analysed using both non-parametric permutation test and two-way ANOVA. The 
continuous variable gestational age was recoded into a dummy variable (preterm/term). In the validation, 
five of the 11 genes (CCSAP, HTRA4, LEP, PLIN2, SASH1) were differently expressed between the cases 
and controls. For five genes (CGB, DEFA1/DEFA1B1, FCGR3A, LGALS14, LYZ) the expression difference 
was dependent on gestational weeks. The expression level of TPBG was affected both by gestational weeks 
and pre-eclampsia. For HTRA4, the expression level in the pre-eclamptic group was affected by weeks of 
gestation, whereas for the control group this effect was not seen. This suggests that the increased HTRA4 
expression might be related to the pre-eclampsia phenotype associated with preterm delivery and fetal 
growth restriction. Indeed, for CCSAP, HTRA4, LEP, PLIN2 and SASH1 log2Cq values inversely corre-
late with birth weight normalised for weeks of gestation in the pre-eclamptic group (data not shown), 
indicating that the expression level of these genes might be related to the amount of placental pathology 
involved. The results from the qPCR validation are shown in Table  4 and in Figs  3 and 4. Excluding 
outliers from the analysis did not change the result significantly. Excluding diabetic patients from the 
analysis did not cause significant changes for majority of the genes. The most notable difference in this 
analysis was that the expression of PLIN2 did not differ statistically significantly between pre-eclamptics 
and controls, but differed between preterm and term placenta (Supplementary Table S8).
Discussion
In the present study, we conducted an RNA-seq analysis to compare gene expression between 
pre-eclamptic and healthy placenta, and found 53 genes that differed in expression between the groups. 
The genes include those previously identified by numerous microarray studies (e.g. BHLHE40, FSTL3, 
HK2, HTRA4, LEP, PVRL4, SASH1, SIGLEC6), but also those that have been reported by only few studies 
Figure 1. Differentially expressed genes in the RNA-seq by subanalysis. Placental samples of nine pre-
eclamptic and nine non-pre-eclamptic women were analysed in pools of three. Three approaches were used 
in the analysis: 1) All samples were included in the analysis, 2) Pre-eclampsia pool 1 was excluded from the 
analysis and 3) Pre-eclampsia pool 3 was excluded from the analysis. PE = pre-eclampsia.
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Gene symbol Function Protein localisation
Log2 FC 
All pools
Log2 FC 
w/o PE1
Log2 FC 
w/o PE3 Up/Down
ACTA2 Smooth muscle cell contractility Cytoplasm − 1.31 ↓ 
ARMS2 Unknown Cytoplasm 2.36 2.26 1.98 ↑ 
ARNT2 Response to hypoxia Nucleus 1.50 ↑ 
BHLHE40 Cell differentiation, growth suppression Nucleus 1.10 ↑ 
BTNL9 Regulation of immune response Membrane 1.82 ↑ 
CCSAP Cilia function, development Cytoplasm 1.20 ↑ 
CGB Maintenance of pregnancy Secreted 1.82 1.33 2.21 ↑ 
CGB1 Possibly implantation Secreted 1.30 1.39 ↑ 
CGB2 Possibly implantation Secreted 1.34 1.47 ↑ 
CGB8 Maintenance of pregnancy Secreted 1.22 1.15 ↑ 
COL17A1 Cell adhesion, negative regulation of cell motility Membrane, secreted 1.10 ↑ 
CORO2A Inflammatory response Cytoplasm 1.86 ↑ 
CXCL9 T-cell chemoattractant Secreted − 3.10 − 3.04 − 2.93 ↓ 
CYP1A1 PAH metabolism Cytoplasm − 5.12 ↓ 
DEFA1 Host defence Cytoplasm, secreted − 2.69 − 3.18 ↓ 
DEFA1B Host defence Cytoplasm, secreted − 2.68 − 3.17 ↓ 
DIO2 Activation of thyroid hormone Cytoplasm 1.59 ↑ 
FCGR3A Antibody-dependent responses, natural killer cell cytotoxicity Membrane, secreted − 1.31 − 1.26 − 1.28 ↓ 
FER1L4 Long noncoding RNA, gene expression regulation No protein product 0.96 ↑ 
FSTL3 Regulation of growth factor activity during development, metabolic homeostasis Secreted 1.35 1.50 1.33 ↑ 
HBB Component of adult hemoglobin Cytoplasm − 1.20 − 1.62 ↓ 
HBG1 Component of fetal hemoglobin Cytoplasm − 1.12 ↓ 
HK2 Glucose metabolism Cytoplasm 1.72 2.09 ↑ 
HLA-DRA Alpha subunit of HLA-DR, presenting antigens to T-cells Membrane − 1.26 − 1.30 − 1.17 ↓ 
HPSE Remodelling of extra-cellular matrix to permit cell movement Secreted 1.08 ↑ 
HTRA4 Degradation of misfolded proteins Secreted 1.32 1.63 1.03 ↑ 
IGFBP1 Binds to insulin-like growth factors, possibly restricts fetal growth Secreted 1.29 ↑ 
KRT6A Epithelial structures, wound healing Cytoplasm − 5.34 − 5.41 − 4.92 ↓ 
LEP
Fetal growth, reproduction, angiogenesis, 
suppression of appetite, regulation of 
immune response
Secreted 2.26 2.67 ↑ 
LGALS14 Trophoblast differentiation Nucleus − 0.98 − 1.05 ↓ 
LOC100129345 Unknown No protein product − 1.09 − 1.35 ↓ 
LYN
Immune response, response to growth 
factors, and cell proliferation, survival, 
differentiation, and migration
Cytoplasm 1.05 ↑ 
LYPD5 Unknown Membrane − 1.28 ↓ 
LYZ Antibacterial activity Secreted − 1.22 − 1.22 ↓ 
MAGEA4 Promotion of cell growth Cytoplasm − 1.71 ↓ 
MYO7B Transport Cytoplasm 1.71 1.82 ↑ 
NCMAP Myelination Membrane − 0.99 ↓ 
NDRG1 Stress and hormone response, cell growth, differentiation, apoptosis Nucleus 1.08 ↑ 
NRIP1 Modulation of transcriptional activity Nucleus 1.31 ↑ 
PLIN2 Lipid accumulation, inhibition of cellular glucose uptake Cytoplasm 1.28 ↑ 
Continued
www.nature.com/scientificreports/
6Scientific RepoRts | 5:14107 | DOi: 10.1038/srep14107
or have not previously been linked to pre-eclampsia (ARMS2, BTNL9, CCSAP, DIO2, FER1L4, HPSE, 
LOC100129345, LYN, MYO7B, NCMAP, NDRG1, NRIP1, PLIN2, SBSPON, SERPINB9, SH3BP5, TET3, 
TPBG, ZNF175).
The results from expression array studies on pre-eclamptic placentae have recently been summarised 
in a systematic review19, in a meta-analysis20, and in a large-scale aggregate analysis5. Kleinrouweler 
and others19 reviewed 30 studies that compared placental gene expression between pre-eclamptic and 
non-pre-eclamptic pregnancies, and defined a meta-signature of 40 transcripts that were reported to be 
differentially expressed in pre-eclampsia by at least three studies. Of the 53 genes identified in our study, 
nine (17.0%) (BHLHE40, CGB, FSTL3, HTRA4, IGFBP1, LEP, PVRL4, SASH1 and SIGLEC6) belong to 
this meta-signature. Furthermore, of the 577 genes that had a log2 fold change ≥ 1 or ≤ −1 in at least one of 
our subanalyses, 15 (2.6%) belong to the meta-signature. These genes with noticeable although not neces-
sarily statistically significant expression difference between the pre-eclamptic and non-pre-eclamptic pla-
centae include many that have been implicated in previous studies, such as FLT1, INHBA, CRH, PAPPA2 
and LHB. Important limitation in the review by Kleinrouweler and others is that only some of the studies 
list a complete set of the differently expressed genes while many report just selected genes, which may 
bias the results. Vaiman and others20 compared mRNA levels between pre-eclamptic and control pla-
centae by utilising raw data from six publicly available microarray datasets, and identified 67 genes that 
were upregulated and 31 genes that were downregulated in pre-eclamptic placentae in at least four out 
of the six datasets. Fourteen (26.4%) of our differently expressed genes (BHLHE40, CCSAP, FSTL3, HK2, 
HTRA4, LEP, LYN, NDRG1, NRIP1, PVRL4, SASH1, SH3BP5, SIGLEC6 and TPBG) and 21 (3.6%) of the 
genes with two-fold expression difference in our data overlapped with these 98 genes. Leavey and others5 
aggregated seven microarray data sets to generate a large set of 173 samples including 77 pre-eclamptics. 
They were able to separate three distinct subclasses of pre-eclampsia based on gene expression, and 
identified 1295 genes that showed altered expression in pre-eclamptic placentae compared to controls, 
as well as 1329 genes whose expression was altered in at least one of the three subclasses they found. 
Twenty-six (49.1%) of the genes differently expressed in our study were differently expressed in at least 
one of their analysis (ACTA2, ARNT2, BHLHE40, BTNL9, CCSAP, CGB1, COL17A1, CORO2A, DIO2, 
FSTL3, HK2, HTRA4, LEP, LYN, LYPD5, MYO7B, NDRG1, NRIP1, PLIN2, PVRL4, SASH1, SERPINB9, 
SH3BP5, SIGLEC6, TPBG, ZNF175). Furthermore, of the genes with log2 fold change between − 1 and 
1 in our analysis, 104 (18.0%) were reported as differently expressed in their study. These comparisons 
show that our study is in high concordance with previous microarray studies, and provides a valuable 
validation of previous results with a novel method. In addition, our study highlights genes not commonly 
reported by previous studies, such as FER1L4, NCMAP, RPS17, SBSPON, and TET3.
The pathway and functional annotation analyses in our data show several biological processes that 
are disturbed in pre-eclamptic placenta. The enrichment of immunological pathways and annotations 
reflects disturbed immunological balance and inflammation in pre-eclamptic placenta. In line with this, 
annotation analysis highlights multiple autoimmune, inflammatory and immunological diseases, which 
Gene symbol Function Protein localisation
Log2 FC 
All pools
Log2 FC 
w/o PE1
Log2 FC 
w/o PE3 Up/Down
PSG10P Unknown No protein product − 1.15 ↓ 
PVRL4 Cell adhesion Membrane, secreted 1.24 ↑ 
RPS17 A component of the ribosomal 40S subunit Cytoplasm − 1.40 − 1.37 − 1.34 ↓ 
S100A8 Multiple functions in immune response, antioxidant function Cytoplasm, secreted − 1.78 ↓ 
SASH1 Inhibition of invasion, growth and proliferation, proinflammatory Intracellular 1.23 1.45 ↑ 
SBSPON Unknown Secreted − 2.28 ↓ 
SERPINB9 GranzymeB inhibition Cytoplasm 0.98 1.28 ↑ 
SH3BP5 Neuroprotection, reduction of oxidative stress Cytoplasm 1.11 ↑ 
SIGLEC6 Binds leptin, affects proliferation, invasion and apoptosis Membrane, secreted 1.33 ↑ 
TET3 DNA methylation process, epigenetic chromatin reprogramming Nucleus 1.30 1.61 ↑ 
THY1 T-cell cell surface glycoprotein Membrane − 1.30 ↓ 
TPBG Promigratory Membrane 1.05 ↑ 
ZNF175 Suppression of viral replication Nucleus 1.30 ↑ 
Table 2.  The genes with altered expression in pre-eclamptic placentae in the RNA-seq. Log2 fold change 
(FC) is shown for the subanalyses where a trancript had a q value < 0.05. PE = pre-eclampsia.
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suggests that they might share partly common disease mechanisms with pre-eclampsia. Immune system 
molecules with altered expression in our study also participate in a wide array of developmental pro-
cesses in placenta such as the development of haematological and vascular systems. Our results clearly 
show unbalance in many tissue development and homeostasis related processes such as cell death, prolif-
eration, angiogenesis, migration and signalling. Many of the significant annotations including occlusion 
of artery, atherogenesis, atherosclerosis, vascular lesion, hypertension and oxidative stress are related to 
cardiovascular disease, emphasising common mechanisms between pre-eclampsia and other vascular dis-
eases. Taken together, our results underline the intertwined processes of impaired vascular system devel-
opment and function and immunological disturbance as most characteristic features of pre-eclamptic 
placenta. These results are in line with the interpretation of pre-eclampsia pathology depicted in the 
review by Staff and others26.
The qPCR expression levels of CCSAP, HTRA4, LEP, PLIN2 and SASH1 inversely correlated with ges-
tational age –normalised birth weight in the pre-eclamptic group, suggesting that the altered expression of 
these genes might be related to the pre-eclampsia phenotype involving impaired placental development. 
For HTRA4, a gene that encodes a serine peptidase responsible for degradation of misfolded proteins, 
there are previous findings in accordance with this interpretation. In addition to elevated HTRA4 mRNA 
and protein expression in pre-eclamptic placentae, serum HTRA4 levels are increased in pre-eclamptics, 
Figure 2. Heat maps by subanalysis showing the log10FPKM + 1 values of 53 transcripts differentially 
expressed in the RNA-seq. Placental samples of nine pre-eclamptic and nine non-pre-eclamptic women 
were analysed in pools of three. CTRL = control, PE = pre-eclampsia. FPKM = Fragments Per Kilobase of 
exon per Million fragments mapped. (A) All samples included in the analysis (B) Pre-eclampsia pool 1 
excluded from the analysis (C) Pre-eclampsia pool 3 excluded from the analysis.
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Pathway ES (+/−)
FDR q value
All pools w/o PE1 w/o PE3
Allograft rejection − < 0.001 < 0.001 < 0.001
Interferon gamma response − < 0.001 < 0.001 < 0.001
Inflammatory response − < 0.001 < 0.001 0.002
Kras signalling up − < 0.001 < 0.001 0.002
Complement − 0.001 0.011 0.002
IL6 JAK STAT3 signaling − 0.001 0.001 0.009
Interferon alpha response − 0.002 < 0.001 0.018
Epithelial mesenchymal transition − 0.009 0.001
Oxidative phosphorylation − 0.022 0.001
Xenobiotic metabolism − 0.023
Coagulation − 0.026 0.038
Angiogenesis − 0.027 0.004
Bile acid metabolism − 0.035
TNFa signalling via NFKb − 0.034
Reactive oxygen species pathway − 0.038
IL2 STAT5 signaling − 0.048 0.034
Protein secretion − 0.009
Table 3.  Pathway analysis results from Gene Set Enrichment Analysis. The hallmark gene sets were 
utilised in the analyses. ES = Enrichment score; a negative ES indicates gene set enrichment at the bottom of 
the ranked list i.e. the genes that were down-regulated in pre-eclampsia. FDR q value = a false discovery rate 
corrected p value, q values < 0.05 are shown in the table.
Gene
Control vs. pre-eclampsia Term vs. preterm
Up/Down*log2FC
Permutation test 
p value1
ANOVA p 
value2 log2FC
Permutation test 
p value1
ANOVA p 
value2
Expression affected by pre-eclampsia status
 LEP 2.81 <0.001 <0.001 1.00 0.255 0.156 ↑ 
 HTRA4 1.96 <0.001 <0.001 1.80 0.0013 0.0173 ↑ 
 SASH1 1.01 <0.001 0.003 0.65 0.110 0.077 ↑ 
 CCSAP 0.64 <0.001 0.005 0.06 0.781 0.672 ↑ 
 PLIN2 0.54 0.037 0.036 0.36 0.174 0.131 ↑ 
Expression affected by gestational age
 DEFA1/DEFA1B − 1.28 0.028 0.098 − 1.49 0.010 0.005 ↓ 
 CGB 0.27 0.446 0.478 1.07 <0.001 0.003 ↑ 
 LYZ 0.10 0.756 0.541 − 0.81 0.003 0.005 ↓ 
 FCGR3A − 0.13 0.513 0.659 − 0.45 0.020 0.029 ↓ 
 LGALS14 − 0.34 0.122 0.082 − 0.45 0.043 0.067 ↓ 
Expression affected by pre-eclampsia status and gestational age
 TPBG 0.89 <0.001 0.004 0.66 0.011 0.011 ↑ PE  ↓ preterm
Table 4.  Quantitative PCR validation of 11 genes with altered expression in pre-eclamptic placentae in 
the RNA-seq. FC: fold change; gw: gestational week; PE: pre-eclampsia. The validation sample consists of 20 
pre-eclamptic and 19 non-pre-eclamptic women, including 8 pre-eclamptic and 9 non-pre-eclamptic women 
from the RNA-seq. 1Non-parametric permutation test conducted to compare control and pre-eclampsia, 
and term (gw ≥ 37 + 0) and preterm (gw < 37 + 0) separately. Cq values normalised for geometric mean 
of reference genes and a calibrator (Δ Δ Cq) were used in the analysis. 2Two-way ANOVA with categorical 
variables pre-eclampsia status (control/pre-eclampsia) and gestational age (< 37 + 0/ ≥ 37 + 0). Log2 Δ Δ Cq 
values were utilised in the analysis. 3Gestational age affects expression level only in the pre-eclamptic group. 
4in pre-eclamptic placenta compared to control placenta or in preterm placenta (gw < 37 + 0) compared to 
term placenta (gw ≥ 37 + 0).
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being higher in early-onset cases and inversely correlating with weight of the baby and placenta27. This 
provides support for the hypothesis according to which elevated HTRA4 expression may be related to 
the early-onset pre-eclampsia associated with fetal growth restriction.
To the authors’ knowledge, this is the first study utilising RNA-seq to explore placental gene expres-
sion differences between pre-eclamptic and non-pre-eclamptic pregnancies. In the RNA-seq, we included 
only placentae from C-sections without contractions in order to exclude the effect of labour on gene 
expression. Placental samples utilised in the study were collected according to a well-defined protocol 
and pooled in groups of three. Pooling potentially minimizes the effect of subject-to-subject variation 
and facilitates the detection of gene expression differences present in majority of the pre-eclamptic pla-
centae. On the other hand, in studies where pooled samples are untagged individual samples cannot be 
analysed separately, outliers cannot be identified and weaker signals present in only subset of the samples 
might be missed. Limitations of the study include the difference in gestational age between the cases and 
controls and a modest sample size in the RNA-seq, issues that were partly addressed by validating a sub-
set of the differently expressed genes in a larger sample set with more comparable gestational age between 
the cases and controls, and also by studying the dependence of the gene expression on gestational age 
in the validation. Difference in gestational age between cases and controls is a common issue in expres-
sion studies of pre-eclamptic placentae: women with severe pre-eclampsia tend to deliver prematurely, 
whereas healthy pregnant controls usually deliver at term. Including premature non-pre-eclamptic pla-
centae as controls does not provide a non-problematic solution because prematurity might be caused by 
Figure 3. Comparison of the placental gene expression in the qPCR validation between 20 pre-eclamptic 
and 19 non-pre-eclamptic women. Eight pre-eclamptic and nine non-pre-eclamptic women from the RNA–
seq were included in the validation. The genes were selected for validation based on differential expression 
in the RNA-seq. ddCq = delta delta Cq, Cq value normalised for geometric mean of reference genes and a 
calibrator.
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infection or other underlying condition that might severely affect placental gene expression. As we were 
not able to control for gestational age in the RNA-seq, some of the observed expression differences might 
be caused by this factor, as seen in the qPCR validation. One of the pre-eclampsia pools in the RNA-seq 
contained a Trisomy 21 placenta, which may increase the phenotypic heterogeneity of the pool. To cir-
cumvent this issue, we analysed the RNA-seq data also without this pool. The median of the delay from 
detachment of placenta to sampling differed 20 minutes between the cases and controls in the RNA-seq, 
but this is unlikely to be a major concern as RNA is shown to be stable for as long as 48 hours in intact 
placental tissue stored at + 428.
Data from differently expressed transcripts in pre-eclamptic placenta is accumulating, and could be 
exploited in clinical applications. Many of the molecules could potentially be deployed in diagnosing 
pre-eclampsia or as predictive biomarkers to detect women at risk of the disease. Furthermore, these 
markers could be used to recognise subphenotypes of pre-eclampsia. Secreted proteins are of special 
interest for these purposes, but also novel approaches such as sequencing of fetal RNA from maternal 
blood (recently reviewed by Oudejans29) provide intriguing options for development of screening tests. 
Genome-wide or targeted RNA-seq from maternal blood would also enable utilising large number of 
non-protein-coding transcripts (in our data e.g. FER1L4 and LOC100129345). Although developing these 
kinds of tests will require solving of various technical problems and gathering of more detailed knowl-
edge on placental gene expression in pre-eclampsia as well as knowledge on temporal gene expression 
during placental development, this approach could offer a large-scale screening method for predicting 
pre-eclampsia risk or clinical outcome.
Figure 4. Comparison of the gene expression in the qPCR validation between preterm (11 from pre-
eclamptic pregnancies and 8 from pregnancies without pre-eclampsia) and term (9 from pre-eclamptic 
pregnancies and 11 from pregnancies without pre-eclampsia) placentae. ddCq = delta delta Cq, Cq value 
normalised for geometric mean of reference genes and a calibrator.
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In this first RNA-seq study on pre-eclamptic placentae we identified several genes involved in the 
biological processes relevant for the development of pre-eclampsia, such as immunological and vascular 
functions. The genes likely include those whose distorted expression is causative and directly involved in 
the development of pre-eclampsia as well as those whose expression levels change secondary to patho-
logical condition seen in pre-eclamptic placenta. To separate causative expression differences from sec-
ondary changes, it would be ideal to study early-pregnancy placental samples collected before the clinical 
onset of the disease. These samples are due to obvious ethical reasons challenging to collect, but surplus 
from diagnostic samples obtained at the first trimester of pregnancy could provide a solution for future 
studies. Many of the proteins or transcripts produced by the genes with altered expression in this study 
could show potential as pre-eclampsia biomarkers, and the suitability of these molecules for predictive 
or diagnostic purposes should be evaluated in future studies.
Materials and Methods
Study subjects. The Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) cohort30 includes 
placental samples from 102 pre-eclamptic and 79 non-pre-eclamptic pregnancies, of which 17 pre-ec-
lamptics and 11 controls met our criteria for the RNA-seq. Nine pre-eclamptic patients and nine healthy 
pregnant women were selected for the RNA-seq, and the samples were pooled in pools of three. The sam-
ples were pooled in order to maximize the number of placental transcriptomes that could be sequenced 
with the resources available. All the cases in pre-eclampsia pool 3, and one case in the pre-eclampsia 
pools 1 and 2 had an early-onset pre-eclampsia (onset < 34 + 0 weeks of pregnancy). The pre-eclampsia 
pools 1, 2 and 3 consist of placental samples from 38–39, 34–36 and 33 weeks of gestation, respec-
tively, and the control pools from 38–39 weeks of gestation. Only term control placentae were utilised 
in the RNA-seq because in prematurely delivered placentae gene expression might be affected by infec-
tion or other unknown factors. Only women who delivered by elective or urgent C-section without 
labour were included to minimize the effect of delivery method on gene expression. Placental samples 
taken within 1.5 hours of placental detachment were considered eligible. Exclusion criteria applied were 
chronic hypertension, cardiovascular disease, diabetes, chronic inflammatory, autoimmune, haemolytic 
and renal diseases, hepatitis, placental ablation, chorioamnionitis, and multiple pregnancy. Additionally, 
placental insufficiency, small-for-gestational age baby (SGA) and gestational hypertension were consid-
ered as exclusion criteria for the controls. After the sequencing had been performed, the pre-eclampsia 
pool 1 was found to contain a Trisomy 21 placenta.
The sample set for the qPCR validation consists of placental samples from 20 pre-eclamptic patients 
and 19 non-pre-eclamptic women from the FINNPEC cohort. The validation sample set includes the 
original cases and controls from the RNA-seq, except for the Trisomy 21 placenta. The exclusion cri-
teria were otherwise the same as in the RNA-seq, but diabetic women, women who had given vaginal 
birth and non-pre-eclamptic women with preterm delivery were included in the validation sample set 
to increase the sample size.
The diagnoses of pre-eclampsia were ascertained based on medical records with the following criteria: 
systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg with new-onset protein-
uria (≥ 0.3 g/24 hours) after 20 weeks of gestation31. Preterm delivery is defined as a delivery occurring 
before 37 weeks + 0 days of pregnancy. Birth weights below − 2.0 SD units (birth weight relative to sex 
and length of gestation) according to Finnish standards32 are classified as SGA. Placental insufficiency is 
defined as uterine artery resistance index or pulsatility index > +2 SD units. The diagnoses were verified 
independently by a research nurse and a study physician.
Ethical approval. All study participants have provided a written informed consent, and the study 
protocols have been approved by the Coordinating Ethics Committee of the Hospital District of Helsinki 
and Uusimaa. All experiments were performed in accordance with the approved guidelines.
Sample collection and RNA extraction. The placental samples were collected according to a 9-site 
protocol where placenta is divided in nine sections, and a biopsy sample is harvested from each of these 
sections. The samples were obtained shortly after detachment of placenta: 70% of the samples were 
collected within half an hour, 92.5% within an hour and the remaining three samples within 80 minutes 
of placental detachment. The samples were subsequently stored in RNA later solution. For each study 
sample, RNA was extracted from two placental fragments (sites 1 and 8 for the RNA-seq and sites 2 and 
4 for the qPCR validation) that were pooled together before the extraction. The RNA was extracted using 
MirVana miRNA Isolation Kit (Invitrogen) (for the RNA-seq) or PureLink® RNA Mini Kit (Invitrogen) 
(for the qPCR validation), and stored in − 80 °C. Integrity of the RNA was evaluated with Bioanalyzer 
2100 (Agilent).
RNA sequencing. The placental transcriptomes were sequenced in Science for Life Laboratory 
(Stockholm, Sweden) with the Illumina sequencing platform. Before the sequencing, the RNA samples 
were pooled in pools of three. The RNA libraries were constructed with Illumina’s TruSeq RNA sam-
ple preparation kit. The clustering was performed on a cBot cluster generation system using a HiSeq 
paired-end read cluster generation kit according to the manufacturer’s instructions. The pools were 
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sequenced on an Illumina HiSeq 2000 as paired-end reads to 100 bp. The sequencing runs were car-
ried out according to the manufacturer’s instructions. Base conversion was performed using Illumina’s 
OLB v1.9.
RNA-seq data analysis. The quality of the raw sequence reads was determined with the FastQC 
and PRINSEQ tools integrated in the Chipster software33. The reads were trimmed with Trimmomatic 
(v. 0.22)34. Bases with quality value < 20 were cut off from the start and end of the reads and adapter 
sequences and reads shorter than 25 bp were removed. Reads containing > 2 undetermined bases (N) 
were removed with the Chipster integrated PRINSEQ tool. After trimming and filtering, the reads were 
aligned to the reference genome (hg19) with Tophat (v. 2.0.4)35. The UCSC hg19 genome sequence 
indexes and the GTF transcript annotation files provided by Illumina were used in the alignment. A 
transcriptome index was built with the control pool 3 and the same index was subsequently utilised for 
the other alignments. The expected mean inner distance between mate pairs was estimated from the 
average total fragment size for each pool. 50 bp was set as the standard deviation for the distribution on 
inner distances between mate pairs. Otherwise, default settings were used for the alignment. The align-
ments were examined with SAMtools36 and HTSeq37 and visualised with the Chipster genome browser. 
Transcript assembly for each individual pool was conducted with Cufflinks (2.0.2)38. Multi read correct 
(-u) and upper quartile normalisation (-N) options were used in the assembly. The assemblies were 
merged together with Cuffmerge. The case and control groups were tested for differential gene expression 
with Cuffdiff. In the Cuffdiff run, multi read correct option (-u) was utilised and the tool was provided 
with the multifasta file the reads were mapped to (-b) to improve accuracy of transcript abundance 
estimates. In the differential expression analysis, a q value (an FDR corrected p value) of < 0.05 was con-
sidered statistically significant. The results were visualised with CummeRbund39 in the R environment.
Pathway and functional annotation analyses were conducted separately for each subanalysis using 
GSEA40,41 and IPA (QIAGEN) software. The gene lists included in the GSEA analysis contained all the 
genes from the Cuffdiff differential gene expression result files except for the Y chromosomal ones and 
the ones for which Cuffdiff had not conducted differential expression test (test status FAIL or NOTEST). 
The analyses were performed with the GSEAPreranked tool, and the log2 fold change values were used 
as ranking values for the genes. Analyses were run twice using two different gene sets separately: the 
hallmark gene sets and the canonical pathways gene sets. The hallmark gene sets represent specific 
well-defined biological processes or states and have been created by computational methodology based 
on identifying gene set overlaps. Canonical pathways gene sets have been collected from pathway data-
bases and have usually been gathered by domain experts. An FDR q value of < 0.05 was considered 
significant in the GSEA analyses. For the analysis conducted with IPA, genes with a log2 fold change 
≥ 1 or ≤ −1 were included. As for the GSEA analyses, the analyses were conducted separately for each 
subanalysis. Genes and endogenous chemicals were included as a reference set, and only experimentally 
observed relationships were considered. A p value of < 0.05 or a corresponding –log(p value) of 1.3 were 
considered significant in the IPA analyses.
Selection of the genes for the qPCR validation. The expression patterns of the genes that were 
differentially expressed between the cases and controls in the RNA-seq were visually evaluated using the 
Chipster genome browser and heat maps produced with CummeRbund. Based on this evaluation, we 
excluded genes that showed clearly overlapping expression pattern between the case and control pools. 
For the qPCR validation we selected genes that showed consistent differential expression across the case 
pools compared to the control pools, and preferred the genes with expression level large enough to be 
detected with qPCR. In addition, functional relevance of the genes for pre-eclampsia was considered in 
the selection process.
Reverse transcription and qPCR. After the RNA extraction, TURBO DNA-free (Invitrogen) DNAase 
treatment was performed for each sample according to the manufacturer’s instructions to degrade any 
genomic DNA. A microgram of placental RNA was reverse transcribed to cDNA with High Capacity 
RNA-to cDNA Kit (Invitrogen) according to the manufacturer’s instructions. Duplicate reverse transcrip-
tion reactions were prepared from each sample.
The qPCR validation was performed with Taqman chemistry (TaqMan® Fast Universal PCR Master 
Mix (2X), No AmpErase® UNG (Applied Biosystems)). The target genes and the Taqman assays utilised 
are listed in Supplementary Table S9. Reaction mixes were prepared according to the manufacturer’s 
instructions, and each sample was run in duplicate in the 7500 Fast Real-Time qPCR machine (Applied 
Biosystems) with the protocol for Taqman Fast chemistry. Before conducting the actual experiments, 
six point standard curves with 1:5 dilutions, except 1:3 dilution for FCGR3A, were prepared for each 
of the target genes to determine the linear range and the most suitable dilution (Supplementary Table 
S9). Endogenous control genes were selected among five candidates (TOP1, PPIA, YWHAZ, UBC and 
TBP) by studying the expression level of these genes in eight cases and in eight controls representative 
of the whole sample set, and evaluating stability of their expression by the geNorm42 and NormFinder43 
software. TBP and YWHAZ were most stably expressed genes in our dataset, and were selected for 
endogenous controls. A cDNA pool constructed from the 19 control samples was utilised as a calibrator 
sample in the qPCR runs.
www.nature.com/scientificreports/
13Scientific RepoRts | 5:14107 | DOi: 10.1038/srep14107
qPCR data analysis. PCR efficiencies were determined with LinRegPCR44,45, and Cq values were 
corrected for efficiency and normalised for geometric mean of the endogenous control genes, and for 
a calibrator sample, with the QPCR software46. The normalised Cq or log2Cq values were used to test 
expression differences between the cases and controls and, additionally, between the preterm and term 
placentae utilising non-parametric permutation test (Δ Δ Cq used) and two-way ANOVA (log2Δ Δ Cq 
used). Statistical analyses were conducted with the QPCR software and IBM SPSS Statistics 21 software 
(IBM Corp).
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